drugset / Trial / NCT04971473

Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal

NCT04971473

Phase 3 Completed 201 enrolled Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NaSingle-groupOpen-labelTreatment

Summary

This is A non-blinded trial. Oral radioiodine was given 24 hours after the second injection of rhTSH, and scanning was done 48 hours after the radioiodine administration. Each patient was scanned first following rhTSH and then scanned after thyroid hormone withdrawal.

Timeline

Start
2021-09-10
Primary completion
2023-07-05
Completion
2023-07-05

Drugs

EvaluationDrugModalityDoseRoute
Subject rhTSH Protein / enzyme biologic 0.9 mg Intramuscular